Wednesday, 4 November 2026
M
Meridian Globe
Live briefing
NTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei AsiaNTT to help Japanese companies update at-risk aging IT with AI— 日经 Nikkei Asia5 things to know about the US midterms and what they mean for Asia— 日经 Nikkei AsiaChina's cable-cutting threat reaches Taiwan and the Philippines— 日经 Nikkei AsiaVienna entrepreneur takes leaders on lux train to China to foster ties— 日经 Nikkei AsiaBangladesh garment factories become second schools for women— 日经 Nikkei AsiaThailand to raise tax on imported EVs to 35% as Chinese brands gain ground— 日经 Nikkei AsiaWhy PC makers are turning back to China— 日经 Nikkei AsiaIndonesia chief of staff sacked for allegedly wiretapping President Prabowo— 日经 Nikkei Asia

Using artificial intelligence for clinical trial quality assurance in a multi-institutional neurovascular-sparing prostate radiotherapy trial

Source Nature 医学研究7d ago
Summary

We index headlines and summaries only. Full content and copyright remain with the original publisher — follow the source link to read it.

Open original
Desk
Health
Region
Global
Language
English
Item ID
health-36317801

Comments 0 comments

No comments yet. Be the first.

Using artificial intelligence for clinical trial quality assurance in a multi-institutional neurovascular-sparing prostate radiotherapy trial · Meridian Globe